Alexandria, VA – [March 18, 2025] – The American Association for the Study of Liver Diseases (AASLD) is inviting members to apply, for their sites, to participate in the TARGET-LD Study which broadly studies outcomes for patients with chronic liver disease (CLD) and cirrhosis. This unique opportunity allows members to apply to join the largest, most comprehensive, and technologically advanced research consortium to evaluate the natural history, care, and health outcomes of patients with liver disease.
The study is grounded in longitudinal clinical care as a foundation for building prospective studies and includes participation in the AASLD Cirrhosis Quality Collaborative (CQC Registry). The CQC Registry prospectively collects data on sets of quality measures across participating sites, to identify variation in process, outcome, and patient reported measures of chronic liver diseases/cirrhosis care as an organized effort with AASLD for shared learning and quality of care improvement.
Two selected sites will gain access to this robust liver disease registry that collects and makes useable real-world clinical data to study and enable high quality decisions on behalf of patients. Member benefits for selected applicants include the following:
- Receive the interactive CQC dashboard which currently provides aggregate results corresponding to core improvement measures to support benchmarking and local care improvement efforts.
- Access to a secure research & data environment for PI/colleagues/fellows to explore available data sample sizes, variables, and attributes to develop publication concepts and refine research questions.
- Tools to filter your site data for several study criteria to determine potential and feasibility for patients’ eligibility in industry sponsored trials and preliminary data collection for grant submissions.
- Use of the Target RWE hosted platform that allows project specific, credentialed users to compile and analyze de-identified data.
- Opportunity to participate in and enroll patients in prospective studies. developed as part of the consortium, and patient-reported outcomes (PROs) and bio-sample collection with support for local research and technical teams efforts in the study.
“Participating CQC sites will not only benefit from access to unparalleled data resources but also gain opportunities for professional growth and collaboration,” said 2025 AASLD President, Grace L. Su, MD, FAASLD. “With support for quality improvement and access to data explorer tools, sites can advance their own research while contributing to the broader hepatology community.”
The CQC Registry is a multisite learning health network led by AASLD dedicated to improving care for patients with cirrhosis through collaboration, data-sharing, and continuous quality enhancement.
The strategic partnership between Target RWE and AASLD is designed to fulfill the unmet need for a large, real-world registry of patients with chronic liver diseases. Utilizing a broad protocol, TARGET-LD collects patient data across multiple sites to identify variations in treatment approaches, outcomes, and patient-reported measures.
Co-Founded by past AASLD president, Michael W. Fried, MD, FAASLD, Target RWE has been a leader in liver disease research since launching TARGET-NASH in 2015. Now expanded into TARGET-LD, this comprehensive registry captures real-world data on diverse subpopulations, including MASLD, MASH, HBV, HCC, PBC, PSC, cirrhosis, Alpha-1, ALD, and Wilson’s disease, providing important insights into disease progression and treatment outcomes.
Sites interested in joining the TARGET-LD and CQC Registry are encouraged to apply now through April 15, 2025.
For more information and to submit your application, please visit aasld.org/cqcregistryapp or contact jpeter@targetrwe.com.
About AASLD
The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. We foster research that leads to improved treatment options for millions of liver disease patients. We advance the science and practice of hepatology through educational conferences, training programs, professional publications and partnerships with government agencies and sister societies.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy. Visit our website to learn more: https://targetrwe.com/
###